Milestone Pharmaceuticals

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
June 2017

Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.

Milestone Pharmaceuticals

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
June 2017

Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.

Milestone Pharmaceuticals

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
June 2017

Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.